Company Encyclopedia
View More
name
Zura Bio
ZURA.US
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 clinical trial development. It is also developing Torudokimab (ZB-880), a monoclonal antibody that neutralizes IL-33 to prevent ST2-dependent and ST2-independent inflammation, which has completed Phase 1/2 clinical studies; and Crebankitug (ZB-168), a monoclonal antibody that binds and neutralizes the IL-7 receptor alpha chain that impact on diseases driven by IL-7 and thymic stromal lymphopoietin immune pathways, which has completed Phase 1/1b clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
1.945 T
ZURA.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Zura Bio Limited Reports Third Quarter 2025 Results

    Zura Bio Limited reported a Q3 2025 net loss of $18 million, with operating expenses at $19.5 million. Despite losses, the company holds $139 million in cash, supporting operations for 12 months. Focused on advancing clinical trials for tibulizumab and exploring new therapeutic indications, Zura Bio invests heavily in R&D. Management is optimistic about addressing unmet medical needs in immunology and the potential of its product candidates.

    Tip Ranks·
    US
    ZURA
    -2.06%
    Tip Ranks·
    US
    ZURA
    -2.06%

    Zura Bio | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    ZURA
    -2.06%
    LB filings·
    US
    ZURA
    -2.06%

    Zura Bio | 8-K: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    ZURA
    -2.06%
    LB filings·
    US
    ZURA
    -2.06%

    Zura Bio reports third quarter net loss of $20.0 million on $139.0 million cash balance

    Zura Bio Ltd. reported a Q3 2025 net loss of $20.0 million, or $0.21 per share, compared to a $22.9 million loss in Q3 2024. R&D expenses rose to $11.9 million due to Phase 2 trials of tibulizumab, while administrative expenses fell to $7.6 million. The company holds $139.0 million in cash, funding operations through 2027, with Phase 2 trial results expected in H2 2026.

    Reuters·
    US
    ZURA
    -2.06%
    Reuters·
    US
    ZURA
    -2.06%

    Zura Bio Ltd expected to post a loss of 18 cents a share - Earnings Preview

    Zura Bio Ltd is expected to report a loss of 18 cents per share for the quarter ending September 30, 2025, with no change in quarterly revenue. The average analyst rating is "buy," with a median 12-month price target of $13.50, representing a 71.6% increase from the last closing price of $3.84. Previous quarterly performances show mixed results, with some earnings beats and misses. The earnings estimate has remained unchanged over the last three months.

    Reuters·
    US
    ZURA
    -2.06%
    Reuters·
    US
    ZURA
    -2.06%
    © 2025 Longbridge｜Disclaimer